[JPM 2026] ABL Bio seeks next license-out after GSK, Eli Lilly deals

ABL Bio is closing in on another partnership with a global pharmaceutical company for its proprietary Grabody-B technology, a ...
FiercePharma

GSK rounds out year of approvals with FDA asthma nod for long-acting biologic Exdensur

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. Tuesday, the U.S. regulator greenlit GSK’s depemokimab, an ultra-long-acting ...
Benzinga.com

GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst

CAMP4 Therapeutics Corporation (NASDAQ: CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE: GSK). The collaboration aims to identify and ...
News.az

RAPT stock soars after $2.2B GSK acquisition deal

The acquisition was announced on Tuesday, News.Az reports, citing Reuters. This marks GSK's first major purchase under the ...
FierceBiotech

GSK cuts the cord on Ideaya collaboration, letting go of 2 programs

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a 2020 licensing agreement. The breakup was initiated by GSK on Dec. 4, Ideaya ...
Seeking Alpha

GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade

GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac litigation ...